Q-omics provides the consensus-scored IDH2-DT profile across patient tissues and cancer cell-line models. IDH2-DT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IDH2-DT is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IDH2-DT RNA expression shows 9,569 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight ACC, KIRC, and SARC as cancer lineages where IDH2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IDH2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IDH2-DT survival associations across molecular data types. IDH2-DT RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IDH2-DT RNA expression–survival associations across cancer types. High IDH2-DT expression shows unfavorable associations in ACC, BLCA, KIRC and CHOL, but favorable associations in HNSC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify ACC as the clearest survival context for IDH2-DT RNA expression.
This table summarizes IDH2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IDH2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IDH2-DT shows lower tumor expression in KIRC, KIRP, HNSC and THCA and higher tumor expression in BRCA and LUSC. The KIRC box plot shows higher IDH2-DT RNA expression in normal versus tumor tissue (log2 FC = −2.127, t-test p < 0.001).
This table shows molecular features associated with IDH2-DT in patient tissues and cancer cell lines. In patient samples, IDH2-DT shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
